A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Thyroid dysfunction, manifesting as either overt or subclinical hypothyroidism, negatively affects lipid metabolism: this leads to hypercholesterolemia which progressively increases the risk for cardiovascular disease and, potentially, mortality. Hypercholesterolemia in hypothyroidism is mainly due to a reduction in low-density lipoprotein (LDL) receptor activity, this accompanied by concomitant diminishing control by triiodothyronine (T3) of sterol regulatory element-binding protein 2 (SREBP-2), which modulates cholesterol biosynthesis by regulating rate-limit degrading enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) activity. Recently, 3,5-diiodothyronine (T2), a natural thyroid hormone derivative, was found to repress the transcription factor carbohydrate-response element-binding protein (ChREBP) and also to be involved in lipid catabolism and lipogenesis, though via a different pathway than that of T3. While thyroid hormone could therapeutically reverse the dyslipidemic profile commonly occurring in hypothyroidism, it should be borne in mind that the potency of the effects may be age-and sex-dependent. Thyroid hormone administration possibly also sustains and enhances the efficacy of hypolipidemic drugs, such as statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9), in patients with dyslipidemia and hypothyroidism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
2013 ETA Guideline: Management of Subclinical Hypothyroidism
Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000356507 · Cited by 877
Self-citationDuntas, L. H. (2002) · Thyroid · doi:10.1089/10507250252949405 · Cited by 725
Self-citationRegulation of Sterol Synthesis in Eukaryotes
Espenshade, P. J., & Hughes, A. L. (2007) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.110306.130315 · Cited by 593
Razvi, S., Ingoe, L., Keeka, G., Oates, C., McMillan, C., & Weaver, J. U. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1869 · Cited by 389
Åsvold, B. O., Vatten, L. J., Nilsen, T. I. L., & Bjøro, T. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02333 · Cited by 350 · cited 1×
“Furthermore, in another cross-sectional study including 30,656 participants, lipid values even within the normal TSH range were directly associated with TSH values in men above 50 years of age (69).”
BackgroundLow-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
Sacks, F. M., & Campos, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030636 · Cited by 241
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237 · cited 1×
“RLPs increase intimal cholesterol deposition and activate several proinflammatory, proapoptotic and procoagulant pathways (35).”
BackgroundJepsen, A.-M. K., Langsted, A., Varbo, A., Bang, L. E., Kamstrup, P. R., & Nordestgaard, B. G. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.253757 · Cited by 218
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212 · cited 1×
“Residual CVD risk is mainly determined by hypertriglyceridemia, elevated small dense LDL particles, reduced HDL-C and HDL particle numbers, increased triglyceride (TG)–rich lipoproteins or remnant lipoproteins (RLPs) and postprandial hyperlipidemia, also known collectively as the atherogenic dyslipidemia complex (32).”
BackgroundNonthyrotoxic Prevention of Diet-Induced Insulin Resistance by 3,5-Diiodo-L-Thyronine in Rats
de Lange, P., Cioffi, F., Senese, R., Moreno, M., Lombardi, A., Silvestri, E., De Matteis, R., Lionetti, L., Mollica, M. P., Goglia, F., et al. (2011) · Diabetes · doi:10.2337/db11-0207 · Cited by 106 · cited 1×
“Transfection studies have shown that T2 does not act via TRβ but through an increase of hepatic nuclear sirtuin 1 (SIRT1) activity that targets peroxisome proliferator-activated receptor (PPAR)-γ coactivator (PGC-1α) and SREBP-1c; these deacetylation processes result in mitochondrial biogenesis and downregulation of l…”
BackgroundThyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway
Goldberg, I. J., Huang, L.-S., Huggins, L. A., Yu, S., Nagareddy, P. R., Scanlan, T. S., & Ehrenkranz, J. R. (2012) · Endocrinology · doi:10.1210/en.2012-1572 · Cited by 80 · cited 1×
“It is noteworthy that in an LDLR knock-out mice study, TH reduced circulating TC and VLDL-C levels by about 70% (85).”
BackgroundLi, X., Wang, Y., Guan, Q., Zhao, J., & Gao, L. (2017) · Clinical Endocrinology · doi:10.1111/cen.13338 · Cited by 66
Cited by
Hepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
“ANGPTL3 is upregulated by liver X receptor (LXR) [45] and downregulated by several factors, including insulin [42,46], leptin [42], peroxisome proliferator-activated receptor-b (PPARb) [47], statins [48], and thyroid hormone [49,50].”
BackgroundWyne, K. L., Nair, L., Schneiderman, C. P., Pinsky, B., Antunez Flores, O., Guo, D., Barger, B., & Tessnow, A. H. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac172 · Cited by 111
“In patients with HT, biosynthesis of new cholesterol is downregulated, yet activity of low-density lipoprotein receptors is also reduced, resulting in increased levels of low-density lipoprotein and total cholesterol; some studies have also shown increased triglyceride and high-density lipoprotein (HDL) levels [20, 21…”
BackgroundSawicka-Gutaj, N., Zawalna, N., Gut, P., & Ruchała, M. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00377-w · Cited by 57
“Furthermore, these hormones stimulate the mobilization and degradation of lipids and de novo synthesis of fatty acids [5].”
BackgroundThyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal
Van Tassell, B., Wohlford, G. F., Linderman, J. D., Smith, S., Yavuz, S., Pucino, F., & Celi, F. S. (2019) · Thyroid® · doi:10.1089/thy.2019.0101 · Cited by 31
Metadata
- Authors
- Duntas, L. H., & Brenta, G.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2018-09-03
- Volume
- 9
- Pages
- 511-511
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2891009351
- Cited by
- 217
- References
- 18
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.